GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sumitomo Pharma Co Ltd (OTCPK:DNPUF) » Definitions » Debt-to-Equity
中文

Sumitomo Pharma Co (Sumitomo Pharma Co) Debt-to-Equity : 1.20 (As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

Sumitomo Pharma Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1,581 Mil. Sumitomo Pharma Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1,280 Mil. Sumitomo Pharma Co's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $2,386 Mil. Sumitomo Pharma Co's debt to equity for the quarter that ended in Dec. 2023 was 1.20.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Sumitomo Pharma Co's Debt-to-Equity or its related term are showing as below:

DNPUF' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.06   Med: 0.21   Max: 1.2
Current: 1.2

During the past 13 years, the highest Debt-to-Equity Ratio of Sumitomo Pharma Co was 1.20. The lowest was 0.06. And the median was 0.21.

DNPUF's Debt-to-Equity is ranked worse than
89.6% of 856 companies
in the Drug Manufacturers industry
Industry Median: 0.285 vs DNPUF: 1.20

Sumitomo Pharma Co Debt-to-Equity Historical Data

The historical data trend for Sumitomo Pharma Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sumitomo Pharma Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.06 0.56 0.47 0.44 0.82

Sumitomo Pharma Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.39 0.82 0.89 0.93 1.20
Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sumitomo Pharma Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sumitomo Pharma Co Debt-to-Equity Distribution

For the Drug Manufacturers industry and Healthcare sector, Sumitomo Pharma Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Sumitomo Pharma Co's Debt-to-Equity falls into.


Sumitomo Pharma Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Sumitomo Pharma Co's Debt to Equity Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(677.728 + 1826.426) / 3043.064
=0.82

Sumitomo Pharma Co's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(1580.675 + 1279.706) / 2386.077
=1.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sumitomo Pharma Co  (OTCPK:DNPUF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Sumitomo Pharma Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Sumitomo Pharma Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Sumitomo Pharma Co (Sumitomo Pharma Co) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sumitomo Pharma Co Ltd (OTCPK:DNPUF) » Definitions » Debt-to-Equity
Comparable Companies
TSE:4540 TSE:4887 TSE:4547 TSE:4521 TSE:4534 TSE:4553 TSE:4569 TSE:4551 TSE:4559 TSE:4886 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 XSWX:SDZ VTRS NBIX
Traded in Other Exchanges
4506:Japan DPM:Germany
Address
6-8, Doshomachi 2-chome, Chuo-ku, Osaka, JPN, 541-0045
Website
https://www.sumitomo-pharma.com
Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.